Dyspnea and Cardiotoxicity in Multiple Myeloma Patients Who Receive Carfilzomib
Risk Factors for Dyspnea and Cardiotoxicity in Patients With Multiple Myeloma Who Receive Carfilzomib: A Prospective Pilot Study
Sponsor: University of Chicago
Terminated
Study terminated by PI
Other terminated trials from University of Chicago
Other Cardiotoxicity trials with similar outcome
Listed as NCT04827563, this observational or N/A phase trial focuses on Cardiotoxicity and Dyspnea and remains terminated or withdrawn. Sponsored by University of Chicago, it has been updated 10 times since 2021, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
10 versions recorded-
Mar 2026 — Present [monthly]
Terminated
Status: Active Not Recruiting → Terminated
-
Feb 2025 — Mar 2026 [monthly]
Active Not Recruiting
-
Sep 2024 — Feb 2025 [monthly]
Active Not Recruiting
-
Aug 2024 — Sep 2024 [monthly]
Active Not Recruiting
Status: Recruiting → Active Not Recruiting
-
Jul 2024 — Aug 2024 [monthly]
Recruiting
▶ Show 5 earlier versions
-
Dec 2023 — Jul 2024 [monthly]
Recruiting
-
May 2023 — Dec 2023 [monthly]
Recruiting
-
Sep 2021 — May 2023 [monthly]
Recruiting
-
Jun 2021 — Sep 2021 [monthly]
Recruiting
Status: Not Yet Recruiting → Recruiting
-
May 2021 — Jun 2021 [monthly]
Not Yet Recruiting
First recorded
Mar 2021
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- University of Chicago
For direct contact, visit the study record on ClinicalTrials.gov .